KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Capital Expenditures (2016 - 2025)

AbbVie (ABBV) has disclosed Capital Expenditures for 14 consecutive years, with $329.0 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 13.06% to $329.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, up 24.64% year-over-year, with the annual reading at $1.2 billion for FY2025, 24.64% up from the prior year.
  • Capital Expenditures for Q4 2025 was $329.0 million at AbbVie, down from $381.0 million in the prior quarter.
  • The five-year high for Capital Expenditures was $381.0 million in Q3 2025, with the low at $143.0 million in Q2 2022.
  • Average Capital Expenditures over 5 years is $222.4 million, with a median of $209.0 million recorded in 2022.
  • The sharpest move saw Capital Expenditures crashed 32.97% in 2021, then surged 53.01% in 2025.
  • Over 5 years, Capital Expenditures stood at $187.0 million in 2021, then rose by 13.9% to $213.0 million in 2022, then dropped by 3.76% to $205.0 million in 2023, then skyrocketed by 41.95% to $291.0 million in 2024, then grew by 13.06% to $329.0 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $329.0 million, $381.0 million, and $269.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.